Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (38)

I-23Elin Svensson

Meta-analysis of rifampicin exposure and mortality in three randomized controlled phase II tuberculosis meningitis trials

Wednesday 10:10-11:40

I-24Robin Svensson

The value of model-based therapeutic drug monitoring in tuberculosis treatment – optimized target for rifampicin

Wednesday 10:10-11:40

I-25

Model-based analysis for the screening and ranking of compounds against Plasmodium Falciparum

Wednesday 10:10-11:40

I-32Pauline Themans

Prediction of meropenem systemic and infection site exposure and open-loop control strategy for optimal drug dosing: a PBPK approach

Wednesday 10:10-11:40

I-33Tjokosela Tikiso

TB/HIV co-treatment with superboosted lopinavir lowers abacavir concentrations in children

Wednesday 10:10-11:40

I-38Iñaki F. Trocóniz

An immune quantitative framework for Hepatitis B viral infection

Wednesday 10:10-11:40

I-40Sami Ullah

Population pharmacokinetic analysis of piperacillin in acute haemorrhagic stroke patients – a cerebral microdialysis study

Wednesday 10:10-11:40

I-62Liviawati Wu

Population Pharmacokinetics and Dosing Simulation of JNJ-64155806 (AL-794) in Healthy Volunteers

Wednesday 10:10-11:40

I-67Jinqiu Yin

Optimizing treatment of cephalosporin-resistant pneumococcal meningitis

Wednesday 10:10-11:40

I-75Chenyan Zhao

Quantification and prediction of the combined effect of minocycline and polymyxin B on multidrug-resistant Klebsiella pneumoniae

Wednesday 10:10-11:40

I-77Yi Zheng

Effect of pregnancy on raltegravir free concentrations

Wednesday 10:10-11:40

II-12Jose Francis

AADAC gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis

Wednesday 15:50-17:20

II-19Silke Gastine

Nonparametric Pharmacokinetic-Pharmacodynamic Modelling of Posaconazole

Wednesday 15:50-17:20

II-20Florence Gattacceca

Pharmacokinetic-Pharmacodynamic (PKPD) model of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine

Wednesday 15:50-17:20

II-21Wei Gao

Viral Dynamics Model Predicts Clinical Efficacy in Hepatitis C Virus (HCV) Infected Patients Using Viral Kinetic Data from Phase 1 Studies

Wednesday 15:50-17:20

II-29Nele Goeyvaerts

Population Pharmacokinetic/Pharmacodynamic of a Toll-Like-Receptor 7 (TLR7) Agonist that Induces IP-10 and ISG15 in Cynomolgus Monkeys

Wednesday 15:50-17:20

II-30Antonio Goncalves

Modelling hepatitis B kinetics in mice treated by a novel TLR-7 agonist, alone or in combination with entecavir

Wednesday 15:50-17:20

II-67Iasonas Kapralos

Population Pharmacokinetics of Anidulafungin in ICU patients

Wednesday 15:50-17:20

II-70Yun Kim

A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects and patients

Wednesday 15:50-17:20

II-73Anne Kümmel

Building predictive longitudinal PKPD models of antimalarial combinations with Phase 2b data

Wednesday 15:50-17:20

II-74Franziska Isabelle Kluwe

Joint model for the characterisation of cefuroxime pharmacokinetics in synovial fluid, interstitial fluid of muscle tissue and plasma

Wednesday 15:50-17:20

III-09Linda Aulin

Quantitative modelling of procalcitonin as a treatment response biomarker in sepsis

Thursday 09:55-11:30

III-16

Modelling waist-hip ratio increase in HIV-infected individuals starting antiretroviral therapy

Thursday 09:55-11:30

III-24Robert Bies

Pharmacokinetic-pharmacodynamic modelling of MK-2048 in ex vivo cervical tissue

Thursday 09:55-11:30

III-25Henrik Bjugård Nyberg

A pediatric population pharmacokinetic model for ethionamide in South African children treated for drug-susceptible or drug-resistant tuberculosis.

Thursday 09:55-11:30

III-30Philippine Eloy

Genetics of nevirapine and anti-tuberculosis drugs pharmacokinetics interaction in HIV-tuberculosis co-infected patients in Mozambique

Thursday 09:55-11:30

III-50Maxwell Chirehwa

Correlates of tuberculosis treatment outcomes: application of regression trees and pharmacodynamic modelling techniques

Thursday 09:55-11:30

III-52Young-Kyung Choi

Population pharmacokinetics of cycloserine in patients with multidrug-resistant tuberculosis

Thursday 09:55-11:30

III-55Perrine Courlet

Comparison of escitalopram pharmacokinetics in HIV infected individuals with an uninfected psychiatric cohort

Thursday 09:55-11:30

III-71Aris Dokoumetzidis

Population pharmacokinetics of teicoplanin in preterm and term neonates with late-onset sepsis

Thursday 09:55-11:30

IV-32Claudio Monteiro Sousa

An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a.

Thursday 15:10-16:40

IV-42Chika Ogami

Population pharmacokinetics of unbound daptomycin in hospital patients with Gram-positive infections

Thursday 15:10-16:40

IV-47Taniya Paiboonvong

Population Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients with Pneumonia

Thursday 15:10-16:40

IV-49Semra Palic

Exploring dose-dependent pharmacokinetics of miltefosine in pediatric visceral leishmaniasis patients from East Africa

Thursday 15:10-16:40

IV-52Navarat Panjasawatwong

Population pharmacokinetics of rifampicin in Vietnamese Children with Tuberculous Meningitis

Thursday 15:10-16:40

IV-58Philippe Pierrillas

PKPD modelling of EYP001a (a novel FXR agonist) in healthy volunteers and Hepatitis B patients

Thursday 15:10-16:40

IV-62Teun Post

An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model for application in hypothesis generation regarding metabolic pathways and perturbations under various conditions

Thursday 15:10-16:40

IV-75Stein Schalkwijk

Exploring Standard and Alternative Darunavir/Ritonavir Dosing Regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modeling

Thursday 15:10-16:40